BB BIOTECH AG

  • WKN: A0NFN3
  • ISIN: CH0038389992
  • Land: Switzerland

Nachricht vom 13.03.2018 | 17:40

BB BIOTECH AG: Shareholders at the general meeting vote in favor of all proposals and approve the dividend of CHF 3.30

DGAP-News: BB BIOTECH AG / Key word(s): AGM/EGM

13.03.2018 / 17:40
The issuer is solely responsible for the content of this announcement.


Media Release of March 13, 2018
 

BB Biotech AG: Shareholders at the general meeting vote in favor of all proposals and approve the dividend of CHF 3.30
 

All proposals of BB Biotech AG's Board of Directors were approved by its shareholders at the Annual General Meeting held today.

Shareholders voted in favor of the proposal to pay out a dividend of CHF 3.30 per share. Payment will be made on March 19, 2018, the date of record is March 16, 2018 and the ex-dividend date is March 15, 2018.

Shareholders elected the previous board members Dr. Erich Hunziker, Chairman, Dr. Clive Meanwell and Prof. Dr. Dr. Klaus Strein to another one-year term of office.

Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00
Dr. Silvia Schanz, ssc@bellevue.ch
Maria-Grazia Iten-Alderuccio, mga@bellevue.ch
Claude Mikkelsen, cmi@bellevue.ch

Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch

TE Communications AG, Bleichestrasse 11, 9000 St. Gallen, Switzerland, Tel. +41 79 423 22 28
Thomas Egger, teg@te-communications.ch
www.bbbiotech.com
 

Company profile
BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

Disclaimer
This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.



13.03.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Hohes Kurspotenzial: „Attraktiver „Value-add“-Immobilienspezialist

Die Coreo AG führt derzeit eine Bezugsrechtskapitalerhöhung durch, in deren Rahmen ein Bruttoemissionserlös von bis zu 16 Mio. € angestrebt wird. Der Liquiditätserlös soll zum Erwerb von Gewerbe- und Wohnimmobilien für den Geschäftsbereich „Value Add“ verwendet werden. Derzeit, also pre money, verfügt die Gesellschaft über ein prognostiziertes NAV (auf Grundlage von GBC-Berechnungen) von 2,40 €. Für das laufende und kommende Geschäftsjahr rechnen wir mit einem spürbaren Ertrags- und Ergebnisanstieg. Neben der Steigerung von Mieterträgen sollte die Gesellschaft im nennenswerten Umfang Veräußerungserlöse erzielen sowie stille Reserven aufdecken. Auf Basis unseres DCF-Bewertungsmodells (post money) haben wir ein Kursziel von 3,10 € ermittelt. Auf Basis des aktuellen Kurses sowie des Platzierungspreises im Rahmen der Kapitalerhöhung von 1,60 € je Aktie lautet unserer Einschätzung KAUFEN.“

Aktuelle Research-Studie

Original-Research: UniDevice AG (von GBC AG): Vorstandsinterview UniDevice AG

18. Dezember 2018